The N^ε-(carboxymethyl)lysine–RAGE axis: putative implications for the pathogenesis of obesity-related complications

References

• World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ. Tech. Rep. Ser.894(i–xii), 1–253 (2000).
   Web of Science ®Google Scholar
• Bray GA. Medical consequences of obesity. J. Clin. Endocrinol. Metab.89(6), 2583–2589 (2004).
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Inflammation and metabolic disorders. Nature444(7121), 860–867 (2006).
   PubMed Web of Science ®Google Scholar
• Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab.89(6), 2548–2556 (2004).
   PubMed Web of Science ®Google Scholar
• Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ. Res.96(10), 1042–1052 (2005).
   PubMed Web of Science ®Google Scholar
• Cook KS, Min HY, Johnson D et al. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science237(4813), 402–405 (1987).
   PubMed Web of Science ®Google Scholar
• Halaas JL, Gajiwala KS, Maffei M et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science269(5223), 543–546 (1995).
   PubMed Web of Science ®Google Scholar
• Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes55(6), 1537–1545 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature372(6505), 425–432 (1994).
   PubMed Web of Science ®Google Scholar
• Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring)14(Suppl. 5), 242S–249S (2006).
   PubMed Web of Science ®Google Scholar
• Calabro P, Yeh ET. Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. Subcell. Biochem.42, 63–91 (2007).
   PubMedGoogle Scholar
• Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol. Cell. Endocrinol.316(2), 129–139 (2009).
   Google Scholar
• Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig. Dis. Sci.54(9), 1847–1856 (2009).
   PubMed Web of Science ®Google Scholar
• Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. Cell131(2), 242–256 (2007).
   PubMed Web of Science ®Google Scholar
• Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology145(5), 2273–2282 (2004).
   PubMed Web of Science ®Google Scholar
• Pou KM, Massaro JM, Hoffmann U et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation116(11), 1234–1241 (2007).
   PubMed Web of Science ®Google Scholar
• Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation116(1), 39–48 (2007).
   PubMed Web of Science ®Google Scholar
• Andersson CX, Gustafson B, Hammarstedt A, Hedjazifar S, Smith U. Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes Metab. Res. Rev.24(8), 595–603 (2008).
   PubMed Web of Science ®Google Scholar
• Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res.96(9), 939–949 (2005).
   PubMed Web of Science ®Google Scholar
• Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol.25(1), 4–7 (2004).
   PubMed Web of Science ®Google Scholar
• Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol.27(11), 2276–2283 (2007).
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J. Clin. Invest.116(7), 1793–1801 (2006).
   PubMed Web of Science ®Google Scholar
• Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J. Clin. Invest.115(5), 1111–1119 (2005).
   PubMed Web of Science ®Google Scholar
• Hosogai N, Fukuhara A, Oshima K et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes56(4), 901–911 (2007).
   PubMed Web of Science ®Google Scholar
• Karalis KP, Giannogonas P, Kodela E, Koutmani Y, Zoumakis M, Teli T. Mechanisms of obesity and related pathology: linking immune responses to metabolic stress. FEBS J.276(20), 5747–5754 (2009).
   PubMed Web of Science ®Google Scholar
• Ozcan U, Cao Q, Yilmaz E et al. Endoplasmic reticulum stress links obesity, insulin action, and Type 2 diabetes. Science306(5695), 457–461 (2004).
   PubMed Web of Science ®Google Scholar
• Monnier VM. Nonenzymatic glycosylation, the Maillard reaction and the aging process. J. Gerontol.45(4), B105–B111 (1990).
   PubMedGoogle Scholar
• Januszewski AS, Alderson NL, Metz TO, Thorpe SR, Baynes JW. Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem. Soc. Trans.31(Pt 6), 1413–1416 (2003).
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes54(6), 1615–1625 (2005).
   PubMed Web of Science ®Google Scholar
• Maillard LC. Action des acides amines sur les sucres: formation des melanoidines par voie methodique. CR Hebd. Seances Acad. Sci.154, 66–68 (1912).
   Google Scholar
• Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia44(2), 129–146 (2001).
   PubMed Web of Science ®Google Scholar
• Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J.344(Pt 1), 109–116 (1999).
   PubMed Web of Science ®Google Scholar
• Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc. Natl Acad. Sci. USA81(2), 583–587 (1984).
   PubMed Web of Science ®Google Scholar
• Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW. N-ε-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem. J.324(Pt 2), 565–570 (1997).
   PubMed Web of Science ®Google Scholar
• Dyer DG, Dunn JA, Thorpe SR et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J. Clin. Invest.91(6), 2463–2469 (1993).
   PubMed Web of Science ®Google Scholar
• Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest.70(2), 138–151 (1994).
   PubMed Web of Science ®Google Scholar
• McCance DR, Dyer DG, Dunn JA et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J. Clin. Invest.91(6), 2470–2478 (1993).
   PubMed Web of Science ®Google Scholar
• Ruderman NB, Williamson JR, Brownlee M. Glucose and diabetic vascular disease. FASEB J.6(11), 2905–2914 (1992).
   PubMed Web of Science ®Google Scholar
• Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J. Biol. Chem.270(17), 10017–10026 (1995).
   PubMed Web of Science ®Google Scholar
• Phillips SA, Thornalley PJ. Formation of methylglyoxal and D-lactate in human red blood cells in vitro. Biochem. Soc. Trans.21(2), 163S (1993).
   Google Scholar
• Rabbani N, Thornalley PJ. The dicarbonyl proteome: proteins susceptible to dicarbonyl glycation at functional sites in health, aging, and disease. Ann. NY Acad. Sci.1126, 124–127 (2008).
   Google Scholar
• Shinohara M, Thornalley PJ, Giardino I et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J. Clin. Invest.101(5), 1142–1147 (1998).
   PubMed Web of Science ®Google Scholar
• Thornalley PJ, Jahan I, Ng R. Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. J. Biochem.129(4), 543–549 (2001).
   PubMed Web of Science ®Google Scholar
• Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry34(11), 3702–3709 (1995).
   PubMed Web of Science ®Google Scholar
• Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of ‘autoxidative glycosylation’ in diabetes. Biochem. J.245(1), 243–250 (1987).
   PubMed Web of Science ®Google Scholar
• Schalkwijk CG, Stehouwer CD, van Hinsbergh VW. Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification. Diabetes Metab. Res. Rev.20(5), 369–382 (2004).
   PubMed Web of Science ®Google Scholar
• Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes40(4), 405–412 (1991).
   PubMed Web of Science ®Google Scholar
• Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes48(1), 1–9 (1999).
   PubMed Web of Science ®Google Scholar
• Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med.28(12), 1708–1716 (2000).
   PubMed Web of Science ®Google Scholar
• Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem.271(17), 9982–9986 (1996).
   PubMed Web of Science ®Google Scholar
• Januszewski AS, Alderson NL, Jenkins AJ, Thorpe SR, Baynes JW. Chemical modification of proteins during peroxidation of phospholipids. J. Lipid Res.46(7), 1440–1449 (2005).
   PubMed Web of Science ®Google Scholar
• Januszewski AS, Jenkins AJ, Baynes JW, Thorpe SR. Lipid-derived modifications of plasma proteins in experimental and human diabetes. Ann. NY Acad. Sci.1043, 404–412 (2005).
   Google Scholar
• Miyata T, Inagi R, Asahi K et al. Generation of protein carbonyls by glycoxidation and lipoxidation reactions with autoxidation products of ascorbic acid and polyunsaturated fatty acids. FEBS Lett.437(1–2), 24–28 (1998).
   PubMed Web of Science ®Google Scholar
• Schleicher E, Weigert C, Rohrbach H, Nerlich A, Bachmeier B, Friess U. Role of glucoxidation and lipid oxidation in the development of atherosclerosis. Ann. NY Acad. Sci.1043, 343–354 (2005).
   Google Scholar
• Metz TO, Alderson NL, Chachich ME, Thorpe SR, Baynes JW. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J. Biol. Chem.278(43), 42012–42019 (2003).
   PubMed Web of Science ®Google Scholar
• Schalkwijk CG, Baidoshvili A, Stehouwer CD, van Hinsbergh VW, Niessen HW. Increased accumulation of the glycoxidation product Nε-(carboxymethyl)lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochim. Biophys. Acta1636(2–3), 82–89 (2004).
   Google Scholar
• Ikeda K, Higashi T, Sano H et al. Nε-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry35(24), 8075–8083 (1996).
   PubMed Web of Science ®Google Scholar
• Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. Nε-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry34(34), 10872–10878 (1995).
   PubMed Web of Science ®Google Scholar
• Ahmed MU, Thorpe SR, Baynes JW. Identification of Nε-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J. Biol. Chem.261(11), 4889–4894 (1986).
   PubMed Web of Science ®Google Scholar
• Anderson MM, Heinecke JW. Production of Nε-(carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes52(8), 2137–2143 (2003).
   Google Scholar
• Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates Nε-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J. Clin. Invest.104(1), 103–113 (1999).
   PubMed Web of Science ®Google Scholar
• Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW. Age-dependent accumulation of Ne-(carboxymethyl)lysine and Ne-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 30(5), 1205–1210 (1991).
   Google Scholar
• Mera K, Nagai R, Haraguchi N et al. Hypochlorous acid generates Nε-(carboxymethyl)lysine from Amadori products. Free Radic. Res.41(6), 713–718 (2007).
   PubMed Web of Science ®Google Scholar
• Nagai R, Ikeda K, Higashi T et al. Hydroxyl radical mediates Nε-(carboxymethyl)lysine formation from Amadori product. Biochem. Biophys. Res. Commun.234(1), 167–172 (1997).
   PubMed Web of Science ®Google Scholar
• Nagai R, Unno Y, Hayashi MC et al. Peroxynitrite induces formation of Nε-(carboxymethyl) lysine by the cleavage of Amadori product and generation of glucosone and glyoxal from glucose: novel pathways for protein modification by peroxynitrite. Diabetes51(9), 2833–2839 (2002).
   Google Scholar
• Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J. Intern. Med.251(2), 87–101 (2002).
   PubMed Web of Science ®Google Scholar
• Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J. Biol. Chem.267(18), 12404–12407 (1992).
   PubMed Web of Science ®Google Scholar
• Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ. Res.86(3), E50–E54 (2000).
   Web of Science ®Google Scholar
• Brouwers O, Teerlink T, van Bezu J, Barto R, Stehouwer CD, Schalkwijk CG. Methylglyoxal and methylglyoxal-arginine adducts do not directly inhibit endothelial nitric oxide synthase. Ann. NY Acad. Sci.1126, 231–234 (2008).
   Google Scholar
• Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest.87(2), 432–438 (1991).
   PubMed Web of Science ®Google Scholar
• Hogan M, Cerami A, Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J. Clin. Invest.90(3), 1110–1115 (1992).
   PubMed Web of Science ®Google Scholar
• Rosca MG, Monnier VM, Szweda LI, Weiss MF. Alterations in renal mitochondrial respiration in response to the reactive oxoaldehyde methylglyoxal. Am. J. Physiol.283(1), F52–F59 (2002).
   PubMed Web of Science ®Google Scholar
• Rosca MG, Mustata TG, Kinter MT et al. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am. J. Physiol.289(2), F420–F430 (2005).
   PubMed Web of Science ®Google Scholar
• Brouwers O, Niessen PM, Haenen G et al. Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia53(5), 989–1000 (2010).
   PubMed Web of Science ®Google Scholar
• Schalkwijk CG, van Bezu J, van der Schors RC, Uchida K, Stehouwer CD, van Hinsbergh VW. Heat-shock protein 27 is a major methylglyoxal-modified protein in endothelial cells. FEBS Lett.580(6), 1565–1570 (2006).
   Google Scholar
• Wu L, Juurlink BH. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension39(3), 809–814 (2002).
   PubMed Web of Science ®Google Scholar
• Lee HJ, Howell SK, Sanford RJ, Beisswenger PJ. Methylglyoxal can modify GAPDH activity and structure. Ann. NY Acad. Sci.1043, 135–145 (2005).
   PubMedGoogle Scholar
• Yao D, Taguchi T, Matsumura T et al. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J. Biol. Chem.282(42), 31038–31045 (2007).
   PubMed Web of Science ®Google Scholar
• Queisser MA, Yao D, Geisler S et al. Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes59(3), 670–678 (2010).
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Humpert PM, Morcos M et al. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med.83(11), 876–886 (2005).
   PubMed Web of Science ®Google Scholar
• Bucciarelli LG, Wendt T, Rong L et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell. Mol. Life Sci.59(7), 1117–1128 (2002).
   PubMed Web of Science ®Google Scholar
• Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation114(6), 597–605 (2006).
   PubMed Web of Science ®Google Scholar
• Kislinger T, Fu C, Huber B et al. Nε-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem.274(44), 31740–31749 (1999).
   PubMed Web of Science ®Google Scholar
• Kislinger T, Tanji N, Wendt T et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol.21(6), 905–910 (2001).
   PubMed Web of Science ®Google Scholar
• Araki N, Higashi T, Mori T et al. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur. J. Biochem.230(2), 408–415 (1995).
   PubMedGoogle Scholar
• Li YM, Mitsuhashi T, Wojciechowicz D et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc. Natl Acad. Sci. USA93(20), 11047–11052 (1996).
   PubMed Web of Science ®Google Scholar
• Vlassara H, Li YM, Imani F et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol. Med.1(6), 634–646 (1995).
   PubMed Web of Science ®Google Scholar
• Ohgami N, Nagai R, Ikemoto M et al. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J. Biol.Chem.276(5), 3195–3202 (2001).
   PubMed Web of Science ®Google Scholar
• Jono T, Miyazaki A, Nagai R, Sawamura T, Kitamura T, Horiuchi S. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett.511(1–3), 170–174 (2002).
   PubMed Web of Science ®Google Scholar
• Neeper M, Schmidt AM, Brett J et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem.267(21), 14998–15004 (1992).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Vianna M, Gerlach M et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem.267(21), 14987–14997 (1992).
   PubMed Web of Science ®Google Scholar
• Nagai R, Mera K, Nakajou K et al. The ligand activity of AGE-proteins to scavenger receptors is dependent on their rate of modification by AGEs. Biochim. Biophys. Acta.1772(11–12), 1192–1198 (2007).
   PubMedGoogle Scholar
• Aldini G, Dalle-Donne I, Colombo R, Maffei Facino R, Milzani A, Carini M. Lipoxidation-derived reactive carbonyl species as potential drug targets in preventing protein carbonylation and related cellular dysfunction. Chem. Med. Chem.1(10), 1045–1058 (2006).
   Web of Science ®Google Scholar
• Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids25(3–4), 275–281 (2003).
   PubMed Web of Science ®Google Scholar
• Aldini G, Dalle-Donne I, Facino RM, Milzani A, Carini M. Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med. Res. Rev.27(6), 817–868 (2007).
   PubMed Web of Science ®Google Scholar
• Suzuki D, Miyata T. Carbonyl stress in the pathogenesis of diabetic nephropathy. Intern. Med.38(4), 309–314 (1999).
   PubMed Web of Science ®Google Scholar
• Shanmugam N, Figarola JL, Li Y, Swiderski PM, Rahbar S, Natarajan R. Proinflammatory effects of advanced lipoxidation end products in monocytes. Diabetes57(4), 879–888 (2008).
   PubMed Web of Science ®Google Scholar
• Requena JR, Fu MX, Ahmed MU et al. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem. J.322(Pt 1), 317–325 (1997).
   PubMed Web of Science ®Google Scholar
• Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J. Biol. Chem.275(28), 21177–21184 (2000).
   PubMed Web of Science ®Google Scholar
• Stitt A, Gardiner TA, Alderson NL et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes51(9), 2826–2832 (2002).
   PubMed Web of Science ®Google Scholar
• Alderson NL, Chachich ME, Youssef NN et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int.63(6), 2123–2133 (2003).
   PubMed Web of Science ®Google Scholar
• Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product Nε-(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest.99(3), 457–468 (1997).
   PubMed Web of Science ®Google Scholar
• Schram MT, Schalkwijk CG, Bootsma AH, Fuller JH, Chaturvedi N, Stehouwer CD. Advanced glycation end products are associated with pulse pressure in Type 1 diabetes: the EURODIAB Prospective Complications Study. Hypertension46(1), 232–237 (2005).
   Google Scholar
• Wautier MP, Massin P, Guillausseau PJ et al. N(carboxymethyl)lysine as a biomarker for microvascular complications in Type 2 diabetic patients. Diabetes Metab.29(1), 44–52 (2003).
   Google Scholar
• Miura J, Yamagishi S, Uchigata Y et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J. Diabetes Complicat.17(1), 16–21 (2003).
   Google Scholar
• Imanaga Y, Sakata N, Takebayashi S et al.In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Atherosclerosis150(2), 343–355 (2000).
   PubMedGoogle Scholar
• Nerlich AG, Schleicher ED. Nε-(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker for local oxidative stress. Atherosclerosis144(1), 41–47 (1999).
   PubMedGoogle Scholar
• Sakata N, Imanaga Y, Meng J et al. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis141(1), 61–75 (1998).
   PubMed Web of Science ®Google Scholar
• Nagai R, Fujiwara Y, Mera K, Otagiri M. Investigation of pathways of advanced glycation end-products accumulation in macrophages. Mol. Nutr. Food Res.51(4), 462–467 (2007).
   Google Scholar
• Basta G, Lazzerini G, Massaro M et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation105(7), 816–822 (2002).
   PubMed Web of Science ®Google Scholar
• Kunt T, Forst T, Harzer O et al. The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules. Exp. Clin. Endocrinol. Diabetes106(3), 183–188 (1998).
   Google Scholar
• Nakamura S, Makita Z, Ishikawa S et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes46(5), 895–899 (1997).
   PubMed Web of Science ®Google Scholar
• Uchida Y, Ohba K, Yoshioka T, Irie K, Muraki T, Maru Y. Cellular carbonyl stress enhances the expression of plasminogen activator inhibitor-1 in rat white adipocytes via reactive oxygen species-dependent pathway. J. Biol. Chem.279(6), 4075–4083 (2004).
   PubMed Web of Science ®Google Scholar
• Unno Y, Sakai M, Sakamoto Y et al. Advanced glycation end products-modified proteins and oxidized LDL mediate down-regulation of leptin in mouse adipocytes via CD36. Biochem. Biophys. Res. Commun.325(1), 151–156 (2004).
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia52(11), 2251–2263 (2009).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta1498(2–3), 99–111 (2000).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest.108(7), 949–955 (2001).
   PubMed Web of Science ®Google Scholar
• Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J. Biol. Chem.283(40), 27255–27269 (2008).
   PubMed Web of Science ®Google Scholar
• Hudson BI, Carter AM, Harja E et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J.22(5), 1572–1580 (2008).
   PubMed Web of Science ®Google Scholar
• Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem.272(28), 17810–17814 (1997).
   PubMed Web of Science ®Google Scholar
• Yeh CH, Sturgis L, Haidacher J et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-κB transcriptional activation and cytokine secretion. Diabetes50(6), 1495–1504 (2001).
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Schiekofer S, Schwaninger M et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes50(12), 2792–2808 (2001).
   PubMed Web of Science ®Google Scholar
• Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res. Rev.1(1), 1–15 (2002).
   PubMed Web of Science ®Google Scholar
• Coughlan MT, Thorburn DR, Penfold SA et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J. Am. Soc. Nephrol.20(4), 742–752 (2009).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Hori O, Chen JX et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest.96(3), 1395–1403 (1995).
   PubMed Web of Science ®Google Scholar
• Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab.280(5), E685–E694 (2001).
   PubMed Web of Science ®Google Scholar
• Yan SF, Yan SD, Herold K, Ramsamy R, Schmidt AM. Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing. Endocrinol. Metab. Clin. North Am.35(3), 511–524; viii (2006).
   Google Scholar
• Wautier JL, Zoukourian C, Chappey O et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest.97(1), 238–243 (1996).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest.91(5), 2155–2168 (1993).
   PubMed Web of Science ®Google Scholar
• Hudson BI, Wendt T, Bucciarelli LG et al. Diabetic vascular disease: it’s all the RAGE. Antioxid. Redox Signal.7(11–12), 1588–1600 (2005).
   PubMed Web of Science ®Google Scholar
• Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab. Res. Rev.17(6), 436–443 (2001).
   PubMed Web of Science ®Google Scholar
• Radoff S, Cerami A, Vlassara H. Isolation of surface binding protein specific for advanced glycosylation end products from mouse macrophage-derived cell line RAW 264.7. Diabetes39(12), 1510–1518 (1990).
   PubMed Web of Science ®Google Scholar
• Cai W, He JC, Zhu L et al. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am. J. Pathol.170(6), 1893–1902 (2007).
   PubMed Web of Science ®Google Scholar
• Vlassara H, Cai W, Goodman S et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J. Clin. Endocrinol. Metab.94(11), 4483–4491 (2009).
   PubMed Web of Science ®Google Scholar
• He CJ, Koschinsky T, Buenting C, Vlassara H. Presence of diabetic complications in Type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol. Med.7(3), 159–168 (2001).
   Google Scholar
• Vlassara H, Cai W, Crandall J et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc. Natl Acad. Sci. USA99(24), 15596–15601 (2002).
   PubMed Web of Science ®Google Scholar
• He CJ, Zheng F, Stitt A, Striker L, Hattori M, Vlassara H. Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease. Kidney Int.58(5), 1931–1940 (2000).
   PubMed Web of Science ®Google Scholar
• Park IH, Yeon SI, Youn JH et al. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol. Immunol.40(16), 1203–1211 (2004).
   Google Scholar
• Raucci A, Cugusi S, Antonelli A et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J.22(10), 3716–3727 (2008).
   PubMed Web of Science ®Google Scholar
• Yonekura H, Yamamoto Y, Sakurai S et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J.370(Pt 3), 1097–1109 (2003).
   PubMed Web of Science ®Google Scholar
• Bucciarelli LG, Wendt T, Qu W et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation106(22), 2827–2835 (2002).
   PubMed Web of Science ®Google Scholar
• Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med.4(9), 1025–1031 (1998).
   PubMed Web of Science ®Google Scholar
• Wendt T, Harja E, Bucciarelli L et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of Type 2 diabetes. Atherosclerosis185(1), 70–77 (2006).
   PubMed Web of Science ®Google Scholar
• Katakami N, Matsuhisa M, Kaneto H et al. Decreased endogenous secretory advanced glycation end product receptor in Type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care28(11), 2716–2721 (2005).
   PubMed Web of Science ®Google Scholar
• Koyama H, Shoji T, Yokoyama H et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol.25(12), 2587–2593 (2005).
   PubMed Web of Science ®Google Scholar
• Katakami N, Matsuhisa M, Kaneto H et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in Type 1 diabetes. Atherosclerosis204(1), 288–292 (2009).
   PubMed Web of Science ®Google Scholar
• Katakami N, Matsuhisa M, Kaneto H et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in Type 1 diabetes patients. Diab. Vasc. Dis. Res.5(3), 190–197 (2008).
   PubMed Web of Science ®Google Scholar
• Katakami N, Matsuhisa M, Kaneto H, Yamasaki Y. Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in Type 2 diabetic patients. Atherosclerosis190(1), 22–23 (2007).
   PubMed Web of Science ®Google Scholar
• Humpert PM, Djuric Z, Kopf S et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with Type 2 diabetes. Cardiovasc. Diabetol.6, 9 (2007).
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yamagishi S, Adachi H et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with Type 2 diabetes. Microvasc. Res.76(1), 52–56 (2008).
   PubMed Web of Science ®Google Scholar
• Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with Type 1 diabetes. Clin. Chem.51(9), 1749–1750 (2005).
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yamagishi S, Adachi H et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with Type 2 diabetes. Mol. Med.13(3–4), 185–189 (2007).
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yamagishi S, Adachi H et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab. Res. Rev.23(5), 368–371 (2007).
   PubMed Web of Science ®Google Scholar
• Nin JW, Ferreira I, Schalkwijk CG et al. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in Type 1 diabetes and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia52(4), 705–14 (2009).
   PubMed Web of Science ®Google Scholar
• Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in Type 2 diabetes. Diabetologia49(11), 2756–2762 (2006).
   PubMed Web of Science ®Google Scholar
• Nin JW, Jorsal A, Ferreira I et al. Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in Type 1 diabetes: a 12-year follow-up study. Diabetes59(8), 2027–2032 (2010).
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science259(5091), 87–91 (1993).
   PubMed Web of Science ®Google Scholar
• Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest.95(5), 2111–2119 (1995).
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest.95(5), 2409–2415 (1995).
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature444(7121), 875–880 (2006).
   PubMed Web of Science ®Google Scholar
• Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol.19(4), 972–978 (1999).
   PubMed Web of Science ®Google Scholar
• Alizadeh Dehnavi R, de Roos A, Rabelink TJ et al. Elevated CRP levels are associated with increased carotid atherosclerosis independent of visceral obesity. Atherosclerosis200(2), 417–423 (2008).
   Google Scholar
• Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am. J. Physiol. Heart Circ. Physiol.288(5), H2031–H2041 (2005).
   PubMed Web of Science ®Google Scholar
• Hak AE, Stehouwer CD, Bots ML et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler. Thromb. Vasc. Biol.19(8), 1986–1991 (1999).
   PubMed Web of Science ®Google Scholar
• Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation102(18), 2165–2168 (2000).
   PubMed Web of Science ®Google Scholar
• Ikeda U, Takahashi M, Shimada K. C-reactive protein directly inhibits nitric oxide production by cytokine-stimulated vascular smooth muscle cells. J. Cardiovasc. Pharmacol.42(5), 607–611 (2003).
   Google Scholar
• De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J. Endocrinol. Invest.25(10), 899–904 (2002).
   PubMed Web of Science ®Google Scholar
• Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes46(5), 860–867 (1997).
   PubMed Web of Science ®Google Scholar
• Shimomura I, Funahashi T, Takahashi M et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat. Med.2(7), 800–803 (1996).
   PubMed Web of Science ®Google Scholar
• Kockx M, Leenen R, Seidell J, Princen HM, Kooistra T. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss. Thromb. Haemost.82(5), 1490–1496 (1999).
   Google Scholar
• van Dielen FM, Buurman WA, Hadfoune M, Nijhuis J, Greve JW. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J. Clin. Endocrinol. Metab.89(8), 4062–4068 (2004).
   PubMed Web of Science ®Google Scholar
• Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes. Rev.3(2), 85–101 (2002).
   PubMedGoogle Scholar
• Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J. Thromb. Haemost.1(7), 1575–1579 (2003).
   PubMed Web of Science ®Google Scholar
• Cancello R, Henegar C, Viguerie N et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes54(8), 2277–2286 (2005).
   PubMed Web of Science ®Google Scholar
• Curat CA, Wegner V, Sengenes C et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia49(4), 744–747 (2006).
   PubMed Web of Science ®Google Scholar
• Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest.112(12), 1796–1808 (2003).
   PubMed Web of Science ®Google Scholar
• Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest.112(12), 1821–1830 (2003).
   PubMed Web of Science ®Google Scholar
• Bouloumie A, Curat CA, Sengenes C, Lolmede K, Miranville A, Busse R. Role of macrophage tissue infiltration in metabolic diseases. Curr. Opin. Clin. Nutr. Metab. Care8(4), 347–354 (2005).
   PubMed Web of Science ®Google Scholar
• Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J. Clin. Invest.116(1), 33–35 (2006).
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes43(11), 1271–1278 (1994).
   PubMed Web of Science ®Google Scholar
• Apovian CM, Bigornia S, Mott M et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler. Thromb. Vasc. Biol.28(9), 1654–1659 (2008).
   PubMed Web of Science ®Google Scholar
• Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J. Clin. Endocrinol. Metab.90(4), 2282–2289 (2005).
   PubMed Web of Science ®Google Scholar
• Christiansen T, Richelsen B, Bruun JM. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int. J. Obes. (Lond.)29(1), 146–150 (2005).
   PubMed Web of Science ®Google Scholar
• Schalkwijk CG, Brouwers O, Stehouwer CD. Modulation of insulin action by advanced glycation endproducts: a new player in the field. Horm. Metab. Res.40(9), 614–619 (2008).
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest.117(1), 175–184 (2007).
   PubMed Web of Science ®Google Scholar
• Lumeng CN, DelProposto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes57(12), 3239–3246 (2008).
   PubMed Web of Science ®Google Scholar
• Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis148(2), 209–214 (2000).
   PubMed Web of Science ®Google Scholar
• Yudkin JS. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int. J. Obes. Relat. Metab. Disord.27(Suppl. 3), S25–S28 (2003).
   PubMed Web of Science ®Google Scholar
• Lieuw-a-Fa ML, Schalkwijk CG, Engelse M, van Hinsbergh VW. Interaction of Nε(carboxymethyl)lysine- and methylglyoxal-modified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. Thromb. Haemost.95(2), 320–328 (2006).
   Google Scholar
• Buetler TM, Leclerc E, Baumeyer A et al. N(ε)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. Mol. Nutr. Food Res.52(3), 370–378 (2008).
   PubMed Web of Science ®Google Scholar
• Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Ann. NY Acad. Sci.1043, 461–466 (2005).
   PubMed Web of Science ®Google Scholar
• Sebekova K, Somoza V. Dietary advanced glycation endproducts (AGEs) and their health effects – PRO. Mol. Nutr. Food Res.51(9), 1079–1084 (2007).
   PubMed Web of Science ®Google Scholar
• Peppa M, Uribarri J, Vlassara H. The role of advanced glycation end products in the development of atherosclerosis. Curr. Diab. Rep.4(1), 31–36 (2004).
   PubMedGoogle Scholar
• Hofmann SM, Dong HJ, Li Z et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes51(7), 2082–2089 (2002).
   PubMed Web of Science ®Google Scholar
• Peppa M, Brem H, Ehrlich P et al. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes52(11), 2805–2813 (2003).
   PubMed Web of Science ®Google Scholar
• Negrean M, Stirban A, Stratmann B et al. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with Type 2 diabetes mellitus. Am. J. Clin. Nutr.85(5), 1236–1243 (2007).
   PubMed Web of Science ®Google Scholar